perphenazine has been researched along with gamma-aminobutyric acid in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Geffen, Y; Gil-Ad, I; Nudelman, A; Rephaeli, A; Ron, H; Savitsky, K; Shpaisman, N; Terasenko, I; Weizman, A | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Arimura, A; Dupont, A; Linthicum, GL; Redding, TW; Schally, AV | 1 |
| Kutin, GV; Kutin, VP | 1 |
| Garg, SK; Kulkarni, SK; Mathur, VS; Shukla, VK | 1 |
| Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I | 1 |
| Antoni, G; Appel, L; Eriksson, C; Geffen, Y; Heurling, K; Kapur, S | 1 |
| Fitzgerald, PB | 1 |
| Anand, R; Davidson, M; Geffen, Y; Keefe, R; Rabinowitz, J | 1 |
1 review(s) available for perphenazine and gamma-aminobutyric acid
| Article | Year |
|---|---|
BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dopamine; Drug Evaluation, Preclinical; gamma-Aminobutyric Acid; Humans; Patents as Topic; Perphenazine; Quantitative Structure-Activity Relationship; Receptors, GABA-A; Schizophrenia | 2010 |
2 trial(s) available for perphenazine and gamma-aminobutyric acid
| Article | Year |
|---|---|
BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans.
Topics: Adult; Antipsychotic Agents; Brain; Brain Mapping; Carbon Radioisotopes; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Humans; Male; Perphenazine; Positron-Emission Tomography; Prolactin; Protein Binding; Raclopride; Receptors, Dopamine D2; Time Factors; Young Adult | 2009 |
Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Cognition Disorders; Dopamine Antagonists; Double-Blind Method; Female; GABA Agonists; gamma-Aminobutyric Acid; Humans; India; Male; Maximum Tolerated Dose; Middle Aged; Perphenazine; Risperidone; Romania; Schizophrenia; United States | 2012 |
7 other study(ies) available for perphenazine and gamma-aminobutyric acid
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphetamine; Dyskinesia, Drug-Induced; Esters; Fluphenazine; gamma-Aminobutyric Acid; Male; Perphenazine; Prodrugs; Prolactin; Rats; Rats, Wistar; Schizophrenia | 2008 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Isolation of gamma-amino butyric acid from pig hypothalami and demonstration of its prolactin release-inhibiting (PIF) activity in vivo and in vitro.
Topics: Animals; Chlorpromazine; Culture Techniques; gamma-Aminobutyric Acid; Haloperidol; Hypothalamus; Monoiodotyrosine; Perphenazine; Pituitary Gland; Prolactin; Sulpiride; Swine | 1977 |
[Complex treatment of obsessive states of different etiology].
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Benactyzine; Diazepam; Drug Therapy, Combination; Female; gamma-Aminobutyric Acid; Humans; Imipramine; Male; Methapyrilene; Middle Aged; Obsessive-Compulsive Disorder; Perphenazine; Trifluoperazine | 1978 |
GABAergic, dopaminergic and cholinergic interactions in perphenazine-induced catatonia in rats.
Topics: Animals; Bromocriptine; Catatonia; Dopamine; Drug Synergism; GABA Antagonists; gamma-Aminobutyric Acid; Injections, Intraventricular; Male; Muscimol; Parasympatholytics; Perphenazine; Piracetam; Rats; Rats, Inbred Strains; Scopolamine; Time Factors; Valproic Acid | 1985 |
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Biological Availability; Brain; Catalepsy; Central Nervous System Stimulants; Dopamine; gamma-Aminobutyric Acid; Hippocampus; Male; Microdialysis; Motor Activity; Perphenazine; Prefrontal Cortex; Prolactin; Radioligand Assay; Rats; Rats, Sprague-Dawley; Rats, Wistar; Schizophrenia; Tissue Distribution | 2009 |